~~<i id='592C3E9F36'><strike id='592C3E9F36'><tt id='592C3E9F36'><pre id='592C3E9F36'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：fashion 2025-10-06 06:11:15 Page View：8

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Marks talks Operation Warp Speed for Rare Diseases
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

PATRICKT.FALLON/AFPviaGettyImagesUnitedHealthGrouphasmadeitclearthatmorepeople,especiallyolderadults

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

DarronCummings/APLONDON—AU.K.governmentagencyonTuesdaysaidthatitwon’trecommendEliLilly’sMounjaro—par